Effect of sucralfate on gastroesophageal reflux in esophagitis.
Gastroesophageal reflux was assessed in 18 patients with endoscopically and histologically verified esophagitis, and 15 asymptomatic normal subjects, by a portable receiving system. The qualitative evaluation of the frequency of reflux episodes, normalized mean pH, normalized mean [H+] and the acid clearance rate is found to be indicative of gastroesophageal reflux. Twelve weeks of treatment with sucralfate in an open clinical trial resulted in a significant reduction of gastroesophageal reflux and the elimination of esophageal mucosal damage. Barrett++'s epithelium was found in a rather high proportion and proved to be resistant to treatment. It is suggested that the observed improvement is due to the barrier protecting properties of sucralfate restoring the motor function of the distal esophagus.
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D013392:Sucralfate; D013997:Time Factors
D013392:Sucralfate; D000535:Aluminum